GlassScriptPhysician profile
Joy Wilkins
NPI 1699551812
$1,027.05
in general payments reported to CMS, 2019-2025
27 companies · $715 in 2025
The $715 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $62.30 · 2024: $249 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.85 | 2025 | Caplyta |
| Abbvie INC. | $101.46 | 2023-2025 | |
| Pfizer INC. | $101.06 | 2024-2025 | |
| Glaxosmithkline, LLC. | $77.82 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $72.80 | 2024-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $48.47 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $44.19 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $38.26 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $34.21 | 2024-2025 | Breztri, Farxiga |
| Esperion Therapeutics, INC. | $33.38 | 2024-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $29.23 | 2025 | Rexulti |
| Lundbeck LLC | $22.74 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $22.17 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.00 | 2024 | Trintellix |
| Genentech USA, INC. | $20.85 | 2025 | Ocrevus Zunovo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.18 | 2023 | Jardiance |
| Shield Therapeutics INC | $19.44 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $19.08 | 2025 | Ajovy |
| Jazz Pharmaceuticals INC. | $19.05 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.71 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.06 | 2025 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.36 | 2025 | Xifaxan |
| Ibsa Pharma INC. | $17.24 | 2025 | Licart, Flector, Tirosint |
| Abiomed | $15.53 | 2024 | Impella |
| Sumitomo Pharma America, INC. | $13.71 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $13.68 | 2024 | Nuzyra |
| Amneal Pharmaceuticals LLC | $13.52 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Wilkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.